Table 5.

The aPLs’ correlations in APS patients, overall.

	aCL IgG	aCL IgM	aβ2GPI IgG	aβ2GPI IgM	aPE IgG	aPE IgM	aPS IgG	aPS IgM	aPT IgG	aPT IgM
aCL IgG	1	0.35 **	0.51 **	0.42 **	0.40 **	0.44 **	0.72 **	0.50 **	0.26 *	0.25 *
aCL IgM	0.35 **	1	0.27 *	0.77 **	0.37 **	0.67 **	0.36 **	0.77 **	0.44 **	0.58 **
aβ2GPI IgG	0.51 **	0.27 *	1	0.37 **	0.40 **	0.44 **	0.37 **	0.50 **	0.26 *	0.34 **
aβ2GPI IgM	0.42 **	0.77 **	0.37 **	1	0.54 **	0.64 **	0.35 **	0.64 **	0.58 **	0.56 **
aPE IgG	0.40 **	0.37 **	0.40 **	0.54 **	1	0.65 **	0.56 **	0.46 **	0.61 **	0.28 *
aPE IgM	0.44 **	0.67 **	0.44 **	0.64 **	0.65 **	1	0.48 **	0.74 **	0.46 **	0.50 **
aPS IgG	0.72 **	0.36 **	0.37 **	0.35 **	0.56 **	0.48 **	1	0.52 **	0.31 **	0.21
aPS IgM	0.50 **	0.77 **	0.50 **	0.64 **	0.46 **	0.74 **	0.52 **	1	0.36 **	0.55 **
aPT IgG	0.26 *	0.44 **	0.26 *	0.58 **	0.61 **	0.46 **	0.31 **	0.36 **	1	0.36 **
aPT IgM	0.25 *	0.58 **	0.34 **	0.56 **	0.28 *	0.50 **	0.21	0.55 **	0.36 **	1

APS—antiphospholipid syndrome; aPLs—antiphospholipid antibodies; aCL—anti-cardiolipin antibodies; aβ2GPI—anti-β2 glycoprotein I antibodies; aPE—anti-phosphatidylethanolamine antibodies; aPS—anti-phosphatidylserine antibodies; aPT—anti-prothrombin antibodies; Ig—immunoglobulin; * p < 0.05; ** p < 0.01.